North America Ocular Drug Delivery Market Growth and Forecast by 2028
North America Ocular Drug Delivery Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Technology (Implantable Ocular Drug Delivery Systems, Particulate Drug Delivery Systems, Nano-Particle Drug Delivery System, and Others), Formulation Type (Liposomes and Nanoparticles, Solution, Emulsion, Suspension, and Ointment), Disease Type (Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Macular Degeneration, Cataract, Diabetic Macular Edema, and Others), and End User (Hospitals, Ophthalmic Clinics, and Ambulatory Surgical Centers)
- Status : Published
- Report Code : TIPRE00025761
- Category : Life Sciences
- No. of Pages : 147
- Available Report Formats :
- Last update date : November 11, 2021
2021 Market Size
US$ 6,286.54 Mn
Base year value
2028 Forecast
US$ 10,622.77 Mn
Projected by 2028
CAGR 2022-2028
7.8 %
Growth rate
Addressable Market
US$ 60,099.81 Mn
(2022-2028)
The ocular drug delivery market in North America is expected to grow to US$ 10,622.77 million by 2028 from US$ 6,286.54 million in 2021. The market is estimated to grow at a CAGR of 7.8% from 2021 to 2028.
Cataract, glaucoma, age-related macular degeneration, diabetic retinopathy, and unaddressed refractive error are among the leading causes of blindness or low vision. Most of the population have or had some eye disorder in their lifetime. As per the World Health Organization (WHO) report "Blindness and vision impairment" published in February 2021, around 2.2 billion people worldwide have a near or distance vision impairment. It has also estimated that the leading cause of vision loss or low vision is cataract (94 million) and uncorrected refractive errors (88.4 million). Further, the other common causes of vision loss are glaucoma (7.7 million), corneal opacities (4.2 million), diabetic retinopathy (3.9 million), and trachoma (2 million). According to the National Eye Institute (NEI), in the US, the number of people with cataracts is expected to double from 24.4 million in 2010 to about 50 million in 2050. Similarly, as per the Factsheet Glaucoma: Facts & Figures 2019, over 3 million people in the US were living with glaucoma. Moreover, as per the Canadian Survey on Disabilities 2017, 1.5 million Canadians had a sight loss, and around 5.59 million had an eye disease which could further lead to sight loss.
Amidst the COVID-19 crisis, the healthcare institutions have witnessed decrees in inpatient visits to clinics to prevent the spread of the COVID-19 in the first and second quarters of 2020. As per the recent study by CDC, the number of medical emergency department (ED) visits has declined 42% during the early COVID-19. As a result, the number of elective eye procedures performed per week in hospitals and clinics has decreased over time. According to an article in Ophthalmology Times, elective procedures have decreased in countries such as the United States. The number of patient visits to examination facilities has reduced by 15%. During the COVID-19 pandemic, ophthalmology lost a considerable share of patient volume; the volume of ophthalmic practice is predicted to have decreased by 81%, owing to a decline in patients seeking care for glaucoma and cataracts surgery.
With the new features and technologies, companies can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the ocular drug delivery market. The North America ocular drug delivery market is expected to grow at a good CAGR during the forecast period.
- This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.
North America Ocular Drug Delivery Market Segmentation
North America Ocular Drug Delivery Market – By Technology
- Implantable Ocular Drug Delivery Systems
- Particulate Drug Delivery Systems
- Nano-Particle Drug Delivery System
- Others
North America Ocular Drug Delivery Market – By Formulation Type
- Solution
- Ointment
- Suspension
- Emulsion
- Liposomes and Nanoparticles
North America Ocular Drug Delivery Market – By Disease type
- Cataract
- Dry Eye Syndrome
- Macular Degeneration
- Glaucoma
- Diabetic Retinopathy
- Diabetic Macular Edema
- Others
North America Ocular Drug Delivery Market – By End User
- Hospitals
- Ophthalmic Clinics
- Ambulatory Surgical Centers
North America Ocular Drug Delivery Market – By Country
- US
- Canada
- Mexico
North America Ocular Drug Delivery Market – Companies Mentioned
- AbbVie Inc.
- Bausch Health Companies Inc.
- Novartis AG
- Clearside Biomedical, Inc
- Ocular Therapeutix, Inc.
- Envisia Therapeutics
- Alimera Sciences, Inc.
- EYEGATE PHARMACEUTICALS, INC
North America Ocular Drug Delivery Report Scope
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 6,286.54 Million |
| Market Size by 2028 | US$ 10,622.77 Million |
| CAGR (2021 - 2028) | 7.8% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Technology
|
| Regions and Countries Covered |
North America
|
| Market leaders and key company profiles |
|
- Comprehensive Market Sizing and Forecast Analysis
- Detailed Segmentation Analysis
- In-Depth Market Dynamics Assessment
- Regional and Country-Level Insights
- Competitive Landscape and Company Benchmarking
- Strategic Business Intelligence
Recent Reports
Testimonials
The Insight Partners provided valuable market intelligence that supported our global go-to-market strategy. Their team was professional, responsive, and attentive to our feedback, providing thoughtful analysis and helpful methodological clarifications throughout the project.
Junmo Kim Chief Financial Officer (CFO), Enertech Co., Ltd.
The Insight Partners' SCADA System Market report is comprehensive, with valuable insights on current trends and future forecasts. The team was highly professional, responsive, and supportive throughout. We are very satisfied and highly recommend their services.
RAN KEDEM Partner, Reali Technologies LTDs
I requested a report on a very specific software market and the team produced the report in a few days. The information was very relevant and well presented. I then requested some changes and additions to the report. The team was again very responsive and I got the final report in less than a week.
JEAN-HERVE JENN Chairman, Future Analytica
We worked with The Insight Partners for an important market study and forecast. They gave us clear insights into opportunities and risks, which helped shape our plans. Their research was easy to use and based on solid data. It helped us make smart, confident decisions. We highly recommend them.
PIYUSH NAGPAL Sr. Vice President, High Beam Global
The Insight Partners delivered insightful, well-structured market research with strong domain expertise. Their team was professional and responsive throughout. The user-friendly website made accessing industry reports seamless. We highly recommend them for reliable, high-quality research services
YUKIHIKO ADACHI CEO, Deep Blue, LLC.
This is the first time I have purchased a market report from The Insight Partners.While I was unsure at first, I visited their web site and felt more comfortable to take the risk and purchase a market report.I am completely satisfied with the quality of the report and customer service. I had several questions and comments with the initial report, but after a couple of dialogs over email with their analyst I believe I have a report that I can use as input to our strategic planning process.Thank you so much for taking the extra time and making this a positive experience.I will definitely recommend your service to others and you will be my first call when we need further market data.
JOHN SUZUKI President and Chief Executive Officer, Board Director, BK Technologies
I wish to appreciate your support and the professionalism you displayed in the course of attending to my request for information regarding to infectious disease IVD market in Nigeria. I appreciate your patience, your guidance, and the fact that you were willing to offer a discount, which eventually made it possible for us to close a deal. I look forward to engaging The Insight Partners in the future, all thanks to the impression you have created in me as a result of this first encounter.
DR CHIJIOKE ONYIA MANAGING DIRECTOR, PineCrest Healthcare Ltd.Reason to Buy
- Informed Decision-Making
- Understanding Market Dynamics
- Competitive Analysis
- Identifying Emerging Markets
- Customer Insights
- Market Forecasts
- Risk Mitigation
- Boosting Operational Efficiency
- Strategic Planning
- Investment Justification
- Tracking Industry Innovations
- Aligning with Regulatory Trends
Get Free Sample for